摘要
目的探讨化疗联合安罗替尼对三阴性乳腺癌患者的预后及用药安全性。方法选取2016年1月—2019年1月我院确诊为三阴性乳腺癌的100例患者作为研究对象,随机分为研究组和对照组。对照组纳入研究后给予单纯化疗,研究组加用安罗替尼,对比研究组和对照组治疗前、治疗6个月及治疗12个月血清PRL及BSP;两组治疗后药物安全性情况;两组治疗后临床疗效。结果通过对比两组血清PRL及BSP指标,提示研究组和对照组治疗前血清PRL及BSP结果比较差异无统计学意义(P>0.05);研究组治疗6个月及治疗12个月血清PRL及BSP低于对照组,两组结果比较差异有统计学意义(P<0.05);两组患者不良反应发生情况均为I级,经过减药后症状好转,提示两组用药安全;研究组和对照组三阴性乳腺癌临床疗比较差异有统计学意义(P<0.05)。结论化疗联合安罗替尼用于三阴性乳腺癌疗效肯定,能够降低血清PRL及BSP水平,用药安全性好。
Objective To explore the prognosis and safety of chemotherapy combined with Anlotinib in patients with triple-negative breast cancer.Methods 100 patients with triple-negative breast cancer diagnosed in our hospital from January 2016 to January 2019 were were selected as the research objects and randomly divided into study group and control group.After being included in the study,the control group was given simple chemotherapy,and the study group was added with Anlotinib.Serum PRL and BSP were compared between the study group and the control group before treatment,6 months of treatment and 12 months of treatment.The drug safety of the two groups after treatment;the clinical effect of the two groups after treatment.Results PRL and BSP indexes were compared between the two groups,suggesting that there was no difference in serum PRL and BSP results before treatment between the study group and the control group(P>0.05).PRL and BSP of the study group were lower than those of the control group at 6 months and 12 months after treatment,and the results of the two groups were different(P<0.05).The occurrence of adverse reactions in both groups was grade I,and the symptoms improved after drug reduction,indicating the safety of drug use in both groups.The clinical treatment of triple negative breast cancer was different between the study group and the control group(P<0.05).Conclusion Chemotherapy combined with Anlotinib for triple negative breast cancer is effective,can reduce the serum PRL and BSP levels,good drug safety.
作者
聂琰
谭博
杨旭
李娜
雷妙
NIE Yan;TAN Bo;YANG Xu;LI Na;LEI Miao(Department of Hematology and Endocrinology,Tumor and Blood Ward,the 82nd Group Army Hospital of the PLA,Baoding Hebei 071000,China;Department of Endocrinology,Baoding First Hospital,Baoding Hebei 071000,China;Department of Anesthesia,Baoding Blue Mountain Medical Beauty Hospital,Baoding Hebei 071051,China)
出处
《中国卫生标准管理》
2021年第2期93-95,共3页
China Health Standard Management
关键词
化疗
安罗替尼
乳腺癌
预后
用药
安全性
chemotherapy
anlotinib
breast cancer
the prognosis
drug use
security
